FPMAJ Confirms Regulatory Compliance Actions Completed for All Generic Drug Discrepancies
To read the full story
Related Article
- FPMAJ Reports Detailed Results of Blanket Self-Inspections for Generic Firms
January 29, 2025
- Japan Requests Self-Inspections for All Generic Firms; Report Due by October-End
April 9, 2024
- Industry Explains Scheme to Deal with New Self-Inspection Asked for All Generic Makers
March 19, 2024
- MHLW to Ask All Generic Makers in Japan to Execute Self-Inspections
March 4, 2024
ORGANIZATION
- Japan’s Generic Use Rate Reaches 86.5% in FY2024: JGA
July 7, 2025
- FPMAJ Confirms Regulatory Compliance Actions Completed for All Generic Drug Discrepancies
July 3, 2025
- Pharma Labor Platform Calls for Inflation-Responsive Drug Pricing Reforms, Opposes CEA Expansion
July 3, 2025
- Japan’s Contract Rep Ratio Hits Record as Biotechs, Foreign Firms Drive Demand
July 1, 2025
- FPMAJ Chair Questions Sakigake as Incentive for Prioritizing Japan R&D
June 24, 2025
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…